Measuring progress can be challenging due to the complex nature of cancer and individual variability in response to treatment. Factors such as fluctuating symptoms, varying side effects, and differing personal goals can complicate assessments. Continuous research and advancements in cancer biomarkers aim to improve the precision of progress measurements.
